# Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions

> **NCT00837915** · NA · COMPLETED · sponsor: **Ranbaxy Laboratories Limited** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets

## Key facts

- **NCT ID:** NCT00837915
- **Lead sponsor:** Ranbaxy Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2002-08
- **Final completion:** 2002-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00837915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00837915, "Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00837915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*